ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium
6.12.2024 12:30:00 CET | ACCESS Newswire | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium.
PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer.
ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on these findings as well as earlier in vivo efficacy studies, ProteinQure has initiated GLP-toxicology studies for PQ203 in support of an anticipated investigational new drug application filing in Q2 of 2025.
"These combined findings confirm the power of our computational drug design platform and its potential to address key challenges in cancer therapy. We are deeply committed to moving PQ203 forward and are eager to bring this innovative treatment to clinical trials." stated Lucas Siow, CEO of ProteinQure.
Phase 1a/b trial initiation for PQ203 is planned for the second half of 2025 and will be coordinated at the Princess Margaret Cancer Center in Toronto and other leading hospitals in North America.
For media inquiries please contact Lucas Siow at lucas@proteinqure.com
SOUCE: ProteinQure Inc.
View the original press release on accesswire.com
ProteinQure Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
IDC Defines the Next Era of Technology Intelligence with the Introduction of IDC Quanta(TM) at Directions 20268.4.2026 17:15:00 CEST | Press release
New AI-powered platform establishes an embedded intelligence layer for the AI economy, delivering decision-grade insight BOSTON, MA / ACCESS Newswire / April 8, 2026 / IDC today opened IDC Directions 2026, its flagship client event, bringing together technology leaders, analysts, and industry experts to examine the forces reshaping the global technology market and to introduce a major evolution in how technology intelligence is delivered. At the center of this year's event is IDC Quanta™, a new AI-powered platform that establishes what IDC defines as the technology intelligence layer for the AI economy. As artificial intelligence accelerates the pace of business and compresses decision cycles, IDC is redefining its role from a destination for research and data to an embedded intelligence capability that delivers trusted insight directly into the workflows where decisions are made. "AI is compressing time across the entire technology market, and that breaks the traditional research mode
DistillerSR Launches the Industry's Most Advanced GenAI Capabilities for Extracting Scientific Literature Evidence8.4.2026 16:00:00 CEST | Press release
DistillerSR's Smart Evidence Extraction Now Fully Automates Text and Table Data at Scale OTTAWA, ON / ACCESS Newswire / April 8, 2026 / DistillerSR, the market leader in AI-enabled literature review automation and evidence management, today announced new fully automated capabilities for its Smart Evidence Extraction (SEE) module. SEE uses purpose-built GenAI to automate end‑to‑end workflows for extracting evidence from scientific literature at scale, while maintaining full auditability and human governance over AI‑generated outputs. As the volume of published research continues to grow exponentially, research teams in the pharmaceutical and medical device industries face increasing pressure to monitor evidence with speed and precision. SEE enables research professionals to accurately find, suggest, explain, extract, and link the supporting evidence within the reference in a human-in-the-loop and fully automated workflow. "The latest version of SEE is designed to move research teams fro
Envision Pharma Group appoints Nick Jones as President, Envision Medical Communications8.4.2026 14:00:00 CEST | Press release
Seasoned technology and life sciences leader to advance AI integration across medical communications FAIRFIELD, CT / ACCESS Newswire / April 8, 2026 / Envision Pharma Group (Envision), a global, technology-enabled solutions partner to the life sciences industry, today announced the appointment of Nick Jones as President, Envision Medical Communications (EMC). In this role, Jones will lead the EMC business, focusing on integrating Envision's industry-leading technology and AI capabilities into its award-winning portfolio of solutions and services. Jones joins the company from ConcertAI, where he served as Senior Vice President and General Manager, Commercial Solutions, leading teams delivering consulting services, AI-driven software-as-a-service solutions, and data products supporting pharmaceutical commercialization. Prior to ConcertAI, he spent over a decade at IQVIA (formerly IMS), leading technology and consulting organizations across the US, Europe, and JAPAC, delivering an integra
EnSmart Power and Powerverse Partner to Unlock the Full Value of EV Charging and Home Energy8.4.2026 08:00:00 CEST | Press release
LONDON, UK / ACCESS Newswire / April 8, 2026 / Powerverse today announces a strategic partnership with EnSmart Power, a global leader in energy storage, power conversion, and smart energy solutions. The partnership combines Ensmart's hardware with Powerverse's intelligent software platform, creating a connected, app-driven home solution that unlocks energy optimisation and flexibility services. Combining EnSmart Power's expertise as one of the UK's largest providers of home energy storage systems and a global specialist in power supplies and power conversion, with Powerverse's AI-driven platform that enables home energy orchestration and maximises participation in energy flexibility, the partnership creates a powerful, end-to-end solution. Together, they empower homes to unlock smarter, cleaner, and more cost-effective energy. "By combining EnSmart's proven hardware expertise with Powerverse's AI-driven orchestration platform, we're unlocking the full potential of the connected home,"
Polaris Renewable Energy Announces Q1 2026 Investor Call Details8.4.2026 01:35:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / April 7, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce it will be holding its Earnings Conference Call and Webcast to report its Q1 2026 Earnings Results on Thursday, May 7th, 2026, at 10:00 am EST. To listen to the call, please dial Toll Free 1888-506-0062 or International Toll-Free Number 973-528-0011 entry code 939001. or URL: https://www.webcaster5.com/Webcast/Page/2773/53516 A digital recording of the earnings call will be available for replay two hours after the call's completion. Replay Call Information: Toronto: 1 877-481-4010, Passcode: 53516 International (toll-free): 1 919-882-2331, Passcode: 53516 Encore Replay Expiration Date: May 21, 2026 About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We are a high-performing and f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom